• 1
    Bartlette RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazole derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis in rat. Int J Immunopharmacol 1985; 7: 718.
  • 2
    Siemasko KF, Chong AS-F, Williams JW, Brenner EG, Finnegan A Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61: 635642.
  • 3
    Chog AS-F, Rezai K, Gebel HM, Finnegan A, Foster P, Xu X-L, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140145.
  • 4
    Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu Y-Z, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 10431049.
  • 5
    Williams JW, Xiao F, Foster P, Clardy C, MacChessney L, Sankary H, et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 12231231.
  • 6
    Barten MJ, Gummert JF, van Gelder T, Shorthouse R, Morris RE. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods 2001; 253: 95112.
  • 7
    Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, et al. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000; 191: 105114.
  • 8
    Miyazawa Y, Tsutsui H, Mizuhara H, Fujiwara H, Kaneda K. Involvement of intrasinusoidal hemostasis in the development of concanavalin A-induced hepatic injury in mice. HEPATOLOGY 1998; 27: 497506.
  • 9
    Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196203.
  • 10
    Mizuhara H, O'Neil E, Ogawa T, Kusunoki C, Otsuka K, Satoh S, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 15291537.
  • 11
    Watanabe Y, Morita M, Akaike T. Concanavalin A induces perforin mediated but not Fas-mediated hepatic injury. HEPATOLOGY 1996; 24: 702710.
  • 12
    Gantner F, Leist M, Lohse A, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. HEPATOLOGY 1995; 21: 190198.
  • 13
    Mizuhara H, Uno M, Seki N, Yamashita M, Ogawa T, Kaneda K, et al. Critical involvement of interferon-γ in the pathogenesis of T cell activation-associated hepatitis and regulatory mechanism of interleukin-6 for the manifestations of hepatitis. HEPATOLOGY 1996; 23: 16081615.
  • 14
    Kusters S, Gantner F, Künstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462471.
  • 15
    Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411452.
  • 16
    Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 1998; 275: G387G392.
  • 17
    Schulze-Osthoff K, Krammer PH, Droge W. Divergent signalling via APO-1/Fas and TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 1994; 13: 45874596.
  • 18
    Liang HS, Fesik W. Three-dimensional structures of proteins involved in programmed cell death. J Mol Biol 1997; 274: 291302.
  • 19
    Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC, Morton DL. Genetic analysis of the human tumor necrosis factor α/cachctin promoter region in a macrophage cell line. J Exp Med 1989; 170: 321326.
  • 20
    Pope RM, Leutz A, Ness SA. C/EBPβ regulation of the tumor necrosis factor a gene. J Clin Invest 1994; 94: 14491455.
  • 21
    Yao J, Mackman N, Edgington TS, Fan S-T. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. J Bio Chem 1997; 272: 1779517801.
  • 22
    Nagaki M, Naiki T, Brenner DA, Osawa Y, Imose M, Hayashi H, et al. Tumor necrosis factor α prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not Fas-mediated apoptosis: role of nuclear factor-κB. HEPATOLOGY 2000; 32: 12721279.
  • 23
    Imose M, Nagaki M, Naiki T, Osawa Y, Brenner DA, Asano T, et al. Inhibition of nuclear factor-κB and phosphatidylinositol 3-kinase/Akt is essential for massive hepatocyte apoptosis induced by tumor necrosis factor α in mice. Liver Int 2003; 23: 386396.
  • 24
    Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002; 169: 51885195.
  • 25
    Papadakis KA, Targan SR. Tumor necrosis factor: biology and therpeutic inhibitors. Gastroenterology 2000; 119: 11481157.
  • 26
    Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition NF-κB activation. Exp Mol Med 2002; 34: 462468.
  • 27
    Laurence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-κB in the resolution of inflammation. Nat Med 2001; 7: 12911297.
  • 28
    Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M, et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 2004; 18: 272279.
  • 29
    Allison AC. Introduction Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 6383.
  • 30
    Ksontini R, Colagiovanni DB, Josephs MD, Edwards IIICK, Tannahil CL, Solorzano CC, et al. Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J Immunol 1998; 60: 40824089.
  • 31
    Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kollias G, et al. In vivo evidence for a function role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997; 27: 28702875.
  • 32
    Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-γ−/− mice, but not in TNF-α−/− mice. Role for IFN-γ in activating apoptosis of hepatocytes. J Immunol 1997; 159: 14181428.
  • 33
    Gantner F, Leist M, Kunsters S, Vogt K, Volk HD, Tiegs G. T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res 1996; 229: 137146.
  • 34
    Kam LY, Targen SR. Cytokine-based therapies in inflammatory bowel disease. Curr Opin Gastroenterol 1999; 15: 302307.
  • 35
    Neurath MF, Becker C, Barbulescu K. Role of NF-κB in immune and inflammatory responses in the gut. Gut 1998; 43: 856860.
  • 36
    Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999; 2: 20952102.
  • 37
    Xu X, Blinder L, Shen J, Bong H, Finnegan A, Williams JW, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/Mps-lpr/lpr mice. J Immunol 1997; 159: 167174.
  • 38
    Rebbaa A, Hurh J, Yamamoto H, Kersey DS, Bremer EG. Ganglioside GMS inhibition of EGF receptor mediated signal transduction. Glycobiology 1996; 6: 399406
  • 39
    Lu J, Yang Z, Jiag J, Wang Z, Zhu P. Regulative effect of p38 MAPK on release of TNF alpha and NO from alveolar macrophages under endotoxin stimulation. Chin J Traumatol 2001; 4: 7577.
  • 40
    Haddad JJ. The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathion (GSH)) in the mechanism of redox signaling mediating MAPK (p38)-deficient regulation of pro-inflammatory cytokine production. Biochem Pharmacol 2002; 63: 305320.
  • 41
    Thurmond RL, Wadsworth SA, Schater PH, Zirin RA, Siekierka JJ. Kinetics of small molecule inhibitor binding to p38 kinase. Eur J Biochem 2001; 268: 57475754.